In Brief: Allegiance/J&J
This article was originally published in The Gray Sheet
Executive SummaryAllegiance/J&J: Baxter health-care product and cost-management services business, set to be spun off later this year, inks three-year preferred supplier agreement with Johnson & Johnson's Ethicon and Ethicon Endo-Surgery businesses. J&J's products will be offered by Allegiance as part of its "best value" strategy which "involves consolidating [Allegiance's] business around preferred products in dozens of supply categories" to "improve service and value" while reducing costs, Allegiance explains...
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.